These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis. Anderson P; Austin J; Lofland JH; Piercy J; Joish VN Dermatol Ther (Heidelb); 2021 Oct; 11(5):1571-1585. PubMed ID: 34268709 [TBL] [Abstract][Full Text] [Related]
12. Impact of comorbidities on the treatment of atopic dermatitis in clinical practice. Werner-Busse A; Kostev K; Heine G; Worm M Int J Clin Pharmacol Ther; 2014 Sep; 52(9):726-31. PubMed ID: 25066227 [TBL] [Abstract][Full Text] [Related]
13. Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs of Targeted Therapy-Eligible Atopic Dermatitis Patients in Taiwan-A Real-World Study. Tang CH; Huang YH; Chuang PY; Wang BCM; Wei CY; Ng KJ; Treuer T; Chu CY Dermatol Ther (Heidelb); 2022 Nov; 12(11):2547-2562. PubMed ID: 36155881 [TBL] [Abstract][Full Text] [Related]
14. Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review. Igelman S; Kurta AO; Sheikh U; McWilliams A; Armbrecht E; Jackson Cullison SR; Kress DW; Smith A; Castelo-Soccio L; Treat J; Boothe WD; Diaz LZ; Levy ML; Patel A; Lee LW; Fraile-Alonso MC; Antaya RJ; Shah S; Kittler N; Arkin L; Siegfried E J Am Acad Dermatol; 2020 Feb; 82(2):407-411. PubMed ID: 31606479 [TBL] [Abstract][Full Text] [Related]
15. Healthcare utilization for atopic dermatitis: An analysis of the 2010-2018 health insurance review and assessment service national patient sample data. Kim S; Lee YS; Yeo J; Lee D; Ko DK; Ha IH PLoS One; 2023; 18(6):e0286449. PubMed ID: 37363912 [TBL] [Abstract][Full Text] [Related]
16. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157 [TBL] [Abstract][Full Text] [Related]
17. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy. Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009 [TBL] [Abstract][Full Text] [Related]
19. An update on the topical and oral therapy options for treating pediatric atopic dermatitis. Glines KR; Stiff KM; Freeze M; Cline A; Strowd LC; Feldman SR Expert Opin Pharmacother; 2019 Apr; 20(5):621-629. PubMed ID: 30601075 [TBL] [Abstract][Full Text] [Related]
20. Effects of variations in access to care for children with atopic dermatitis. Siegfried EC; Paller AS; Mina-Osorio P; Vekeman F; Kaur M; Mallya UG; Héroux J; Miao R; Gadkari A BMC Dermatol; 2020 Dec; 20(1):24. PubMed ID: 33341118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]